Leipzig – The Munich-based Venitus Group has acquired a stake in Thinkport, a pioneer in the development of innovative cloud technologies. The founders Dominik Fries and Tobias Drechsel will retain a significant stake in the company and keep their positions unchanged. The partnership with Venitus marks a significant milestone in the development of the cloud consulting company. It will help to further consolidate Thinkport's position as an innovation leader, accelerate growth and lay the foundations for the next phase of development. The parties involved have agreed not to disclose further details of the transaction.A CMS team led by Dr. Kevin Schmidt provided comprehensive legal advice to the Thinkport founders on the transaction. Thinkport, headquartered in Frankfurt/Main with offices in Leipzig, Hamburg and Berlin, has made an impressive journey from a start-up to an established and award-winning player in the cloud technology industry over the past five years. Founded in 2018 and employing around 80 people, the company supports large German-speaking companies and DAX-listed corporations with projects in the areas of cloud migration, development and training. Its customer portfolio includes renowned names such as Edeka, Bayer and Deutsche Bahn. The Venitus Group is a leading digitalization partner for medium-sized and enterprise customers in the DACH region with a focus on the areas of public cloud, data engineering and AI. Venitus complements its organic growth with an acquisition strategy and currently consists of four innovative and fast-growing companies in these areas. Press Con­tact presse@cms-hs. com

Munich – CMS advises the sellers of Cardior Pharmaceuticals in the potential acquisition of the company by Novo Nordisk. Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure. The closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions. It is expected to happen in the second quarter of 2024.A CMS team headed by Lead Partners Stefan-Ulrich Müller, Dr Tilman Weichert and Jörg Schrade advised the sellers of Cardior Pharmaceuticals on all legal aspects of the transaction. Cardior Pharmaceuticals GmbH, based in Hannover, Germany, is a leading clinical-stage bio­phar­ma­ceut­ic­al company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. CMS Germany Stefan-Ulrich Müller, Lead Partner Dr Tilman Weichert, Lead Partner Dr Michael Wangemann, Partner Dr Kai Wallisch, Partner Dr Thomas Mühl, Principal Coun­sel Se­basti­an Hummel, Senior As­so­ci­ate Vikt­or­ia Barthel, Senior As­so­ci­ate Mar­i­elouise Emmer, Senior Associate Dr Carl-Friedrich Thoma, Senior Associate Dr Stefan Kühl, Senior Associate Dr Alexander Weinhold, Senior Associate Maria Kucher, Associate Jonas Ohmann, Associate Dr Josephine Doll, Associate Dr Christian Seeburger, Associate Sonja Schanze, Associate, all Corporate/M&A Dr Marie-Luisa Loheide, Associate, Private Clients Jörg Schrade, Lead Partner Eduard Kosavtsev, Senior Associate, both Tax Stefan Lehr, Partner, Antitrust, Competition & Trade Stefan Lüft, Partner, IP Dr Benedikt Forschner, Partner, Labor, Employment & Pensions Dr Markus Kaulartz, Partner Dr Fiona Savary, Counsel Dr Felix Glocker, Senior Associate, all TMC Dr Tilman Niedermaier, Partner Susanne Schwalb, Partner, both Dispute ResolutionPress Con­tact presse@cms-hs. com

Munich – Family-owned firm Pfeifer & Langen has taken a majority stake in Rügenwalder Mühle, a branded manufacturer that is considered a pioneer in vegetarian/vegan alternatives to meat and sausages...

Munich - Global wireless communications infrastructure provider Phoenix Tower International is acquiring the German subsidiary of Dutch NOVEC BV. Berlin-based Novec GmbH is an independent provider of...

Incorporating ESG KPIs into directors’ remuneration The urgent need to place sustainability at the heart of company strategy is inextricably linked to incentives provided to its directors and employees. This Expert Guide aims to provide practical insights into key market practices and trends aimed at incorporating sustainability and/or Environmental, Social and Governance (“ESG”) KPIs into directors’ remuneration. The regulations and recommendations on ESG-related remuneration vary considerably from sector to sector and from country to country. The trend is, however, undoubtedly towards providing directors (and in some cases senior/mid-level managers) with an incentive to commit to ESG objectives designed to support and promote effective management of sustainability risks. We hope this guide provides the practical roadmap you need to further your business’s sound remuneration practices – wherever in the world you need to operate. For further legal support and advice, get in touch with your regular CMS contact or email us at em­ploy­ment@cmsleg­al. com.

Munich – Factor Eleven, a leading digital marketing software company, announces a strategic collaboration with Armira, an investment holding company focused on family businesses and tech­no­logy. The...

Berlin – Commercial law firm CMS Germany has appointed four new partners with effect from the turn of 2022/2023. These appointments strengthen the partnership in the strategically important Employment...

Munich – Germany’s oldest privately-owned dairy, Milchwerk Jäger GmbH, is merging with Austrian firm Gmundner Molkerei eGen to create a joint dairy business. The two companies have been working together...